ERYTECH Reports Determination of the Recommended Pivotal Phase 3 Dose of eryaspase in its U.S. Phase 1 Study in First Line Adult ALL
ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the determination of the recommended pivotal Phase 3 dosing from its U.S. Phase 1 dose escalation study with eryaspase (GRASPA®) in first line treatment of adult ALL patients.
The U.S. Phase 1 study with eryaspase (GRASPA) is an open label dose escalation study evaluating the safety of eryaspase in combination with CALGB 8811 protocol for first line treatment of adult ALL patients. The study is performed at five clinical sites across the United States. Prof. Dr. Richard Larson, director of the Hematologic Malignancies Clinical Research Program at the University of Chicago, is the principal investigator of the study.
ERYTECH recently announced that all patients had been treated in the third dose escalation cohort of this Phase 1 study. The steering committee of the study reviewed the safety data of all three treatment cohorts and agreed to pursue further development at the dose level of 100 U/kg. This dose level had been previously recommended following ERYTECH’s Phase 2 study in elderly ALL patients. It is also the dose level used in the Phase 2b study in second line, metastatic pancreatic cancer, that recently reported positive efficacy and safety results, and in the ongoing Phase 2b study in AML, from which top-line results are expected by the end of this year.
In parallel with running an expansion cohort of this Phase 1 study at this recommended dose, ERYTECH will potentially initiate the steps toward the launch of a pivotal Phase 3 study in first line adult ALL patients at this dose level.
About ERYTECH and eryaspase (GRASPA®): www.erytech.com
Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH’s initial focus is on the development of products that target the amino acid metabolism of cancer, depriving them of nutrients necessary for their survival.
The company’s lead product, eryaspase, also known under the trade name GRASPA®, consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells. L-asparaginase has been a standard component of multi-agent chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), but side effects limit treatment, especially in adults and patients with weak performance status. With its improved safety profile, eryaspase aims to provide L-asparaginase to patients who cannot tolerate current non-encapsulated asparaginases.
Eryaspase achieved positive efficacy and safety results in a Phase 2 study in elderly patients with ALL, and a Phase 2/3 study in children and adults with relapsed or refractory ALL. ERYTECH believes that the positive results of its Phase 2b clinical study in second-line metastatic pancreatic cancer are significant indicators of eryaspase as a potential treatment approach in solid tumors. ERYTECH also has an ongoing Phase 1 clinical study of eryaspase in the United States in adults with newly diagnosed ALL and a Phase 2b clinical study in Europe in elderly patients with newly diagnosed acute myeloid leukemia (AML), each in combination with chemotherapy.
ERYTECH produces eryaspase at its own GMP-approved and operational manufacturing site in Lyon (France), and at a site for clinical production in Philadelphia (USA). ERYTECH has entered into licensing and distribution partnership agreements for eryaspase for ALL and AML in Europe with Orphan Europe (Recordati Group), and for ALL in Israel with TEVA, which will market the product under the GRASPA® brand name. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designations for eryaspase for the treatment of ALL, AML and pancreatic cancer.
In addition to eryaspase, ERYTECH is developing two other product candidates, erymethionase and eryminase, that focus on using encapsulated enzymes to target cancer metabolism and induce tumor starvation. ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme replacement therapies (ERYZYME).
ERYTECH is listed on Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP) and is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. ERYTECH is also listed in the U.S. under an ADR level 1 program (OTC, ticker EYRYY).
This press release contains forward-looking statements, forecasts and estimates with respect to the clinical development plans, business and regulatory strategy, and anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH's control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Documents filed by ERYTECH Pharma with the French Autorité des Marchés Financiers (www.amf-france.org), also available on ERYTECH’s website (www.erytech.com) describe such risks and uncertainties. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law.
Director of Investor Relations
+33 4 78 74 44 38
+1 917 312 5151
The Ruth Group
+1 646 536 7012
+1 508 280 6592
+33 1 44 71 98 52
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
New Data for Darzalex®▼(daratumumab) Presented at ASH 2017 Show Feasibility of Subcutaneous Use and Potential of Darzalex as a Treatment for Smouldering Multiple Myeloma12.12.2017 11:00 | Tiedote
Janssen-Cilag International NV (“Janssen”) today announced new data from the Phase 1b PAVO clinical study, which demonstrated that the subcutaneous delivery of Darzalex® (daratumumab) co-formulated with recombinant human hyaluronidase enzyme (daratumumab-SC), was generally well-tolerated, with a 12 percent rate of infusion-related reactions (IRRs), in patients with relapsed or refractory multiple myeloma.1 These data were featured as an oral presentation at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta. Daratumumab is currently approved for intravenous (IV) administration, and results from the PAVO trial serve as the basis for an actively enrolling Phase 3 study comparing subcutaneous administration of daratumumab over 3-5 minutes with the approved IV administration in relapsed and refractory multiple myeloma patients.2 Daratumumab is currently indica
The Country Network (TCN) Debuts in Ultra HD with SES12.12.2017 10:55 | Tiedote
The Country Network (TCN), an emerging over-the-air television network devoted to showcasing rising and established country music stars, has joined SES’s successful Ultra HD platform to launch its 4K channel and boost its audience reach. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171211006280/en/ The Country Network (TCN) Debuts in Ultra HD with SES (Photo: Business Wire) SES today announced The Country Network (TCN) has debuted its first shows in Ultra HD this week and become the eleventh 4K channel on SES’s all-in-one Ultra HD solution. The unique Ultra HD platform packages satellite distribution, reception gear, and the world’s largest 4K channel line-up for cable and IPTV operators of all sizes across North America. First launched in 2009, The Country Network is currently enj
World’s First Ultra HD HDR Travel Channel Travelxp 4K Makes German Debut on HD+ via SES12.12.2017 10:55 | Tiedote
Travelxp 4K, one of the world’s leading travel and lifestyle television channels, will start delivering its programmes in Ultra HD (UHD) and High Dynamic Range (HDR) to HD+ viewers across Germany as of 13 December 2017. The channel will be broadcast via Astra 19.2 degrees East and will rely on MX1 for playout and uplink services. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171211006262/en/ World’s First Ultra HD HDR Travel Channel Travelxp 4K Makes German Debut on HD+ via SES Travelxp 4K is also one of the first networks in the world to broadcast in High Dynamic Range, a feature that provides better contrast and greatly improves the viewer experience. Thanks to that technology, HD+ customers can enjoy holiday destinations from around the world from the comfort of their own homes without any additio
Dialog Semiconductor Power Conversion Chipset Used in HUAWEI's Latest Flagship Mate 10 Series12.12.2017 10:13 | Tiedote
Dialog Semiconductor plc (XETRA: DLG), a provider of highly integrated power management, AC/DC power conversion, and low power connectivity technology, today announced that Dialog's RapidCharge(TM) chipset enabling the SuperCharge protocol was selected for the new HUAWEI Mate 10, HUAWEI Mate 10 Pro and Porsche Design HUAWEI Mate 10 smartphone adapters. As fast charging smartphone adoption accelerates, this represents another significant milestone in the company's AC/DC power conversion leadership as Dialog continues to maintain a market share above 60%. HUAWEI recently launched their impressive Mate 10 series with breakthrough AI devices that combine innovative hardware and software. The Kirin 970 chipset and EMUI 8.0 is the world's first AI processor for smartphones with a dedicated Neural Network Processing Unit (NPU). All HUAWEI Mate 10 series sport the New Leica Dual
Russian Teen Star Polina Butorina Releases Her Debut Album in Dubai12.12.2017 10:00 | Tiedote
UAE-based Russian teen actor and singer-songwriter Polina Butorina released her debut album, titled ‘Ocean of Emotions’, here. The anthology of 10 original English songs are written and sung by the 15-year-old student of Raffles International School Dubai. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171211006370/en/ Polina Butorina at the launch of debut album "Ocean of Emotions" - (Photo: AETOSWire) The album was launched simultaneously with the premiere of the recent Hollywood motion picture ‘Maximum Impact’, in which Polina played a main role. The album’s three tracks – ‘Higher Than the Sky’, ‘I Want to Be Free’ and ‘Like Thunder’ were part of the movie’s soundtrack. Launching the album, Polina said, “The album explores the idea of love in its different appearances. The main concept r
IDEMIA Has Been Selected by WiZink to Launch Samsung Pay in Spain12.12.2017 09:00 | Tiedote
IDEMIA, the global leader in trusted identities for an increasingly digital world, announced WiZink, a bank that specializes in credit cards and simple savings solutions that respond to its customers’ day-to-day needs, has selected IDEMIA to roll out the Samsung Pay mobile payment service. IDEMIA has been producing WiZink cards since the bank launched its new brand in June 2016. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171211006319/en/ (Photo: Business Wire) Backed by IDEMIA, WiZink cards can be digitalized and used with Samsung Pay for all users, while also benefiting from all innovative Samsung features and options that Samsung Pay users can access. With the novel and convenient payment method, users can add all loyalty memberships and vouchers to the same wallet under the s
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme